Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multicenter, First Part Randomized, Placebo-controlled, Parallel-group, Double-blind Period Followed by Open-label Trial Period to Evaluate Clinical Safety & Efficacy of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease: Proof-of-concept Study

NCT05423522 is registered in ClinicalTrials.gov with Medesis Pharma SA as lead sponsor.

NCT NCT05423522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05423522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multicenter, First Part Randomized, Placebo-controlled, Parallel-group, Double-blind Period Followed by Open-label Trial Period to Evaluate Clinical Safety & Efficacy of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease: Proof-of-concept Study
Lead sponsor
Medesis Pharma SA
Phase
Phase 2
Overall status
Completed
Start date
May 20, 2022
Completion date
October 29, 2024
Enrollment
72 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease